Patents Examined by My-Chau T Tran
  • Methods and compositions for treatment of epithelial wounds
    Patent number: 9974783
    Abstract: The invention relates to treatment of epithelial wounds. In particular, the invention relates to methods and formulations for treating epithelial wounds based on application of an opioid antagonist such as naltrexone.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: May 22, 2018
    Assignee: The Penn State Research Foundation
    Inventors: Ian S. Zagon, Patricia J. McLaughlin, Joseph W. Sassani
  • Statins in the treatment of muscular dystrophies and myopathies
    Patent number: 9974767
    Abstract: The invention provides methods and compositions for treating neuromuscular diseases including, but not limited to muscular dystrophies. It is demonstrated herein that statin drugs are therapeutic for neuromuscular disease, including, but not limited to muscular dystrophies.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: May 22, 2018
    Assignee: University of Washington
    Inventors: Stanley C. Froehner, Nicholas P. Whitehead
  • Intravenous administration of tramadol
    Patent number: 9968551
    Abstract: A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously in a dosing regimen which includes one or more loading doses administered at shortened intervals as compared to dosing at steady-state is disclosed. In preferred embodiments, the intravenous dosing regimen provides a Cmax and AUC of tramadol is similar to the Cmax and AUC of an oral dose of 100 mg tramadol HCl given every 6 hours. In certain preferred embodiments, the dosing regimen comprises 50 mg IV tramadol at Hour 0, followed by 50 mg at Hour 2, 50 mg at hour 4, and 50 mg every 4 hours thereafter (e.g., until the patient no longer requires treatment with tramadol).
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: May 15, 2018
    Assignee: Revogenex Ireland Ltd
    Inventors: Lucy Lu, Scott Reines, Jeffrey Ping
  • Method of inhibiting DYRK1B
    Patent number: 9951050
    Abstract: The present invention relates to a DYRK1B inhibitor for use in the treatment of cancer, wherein in said cancer and/or in cells of said cancer the hedgehog signaling pathway is activated, and in particular the activation of the hedgehog signaling pathway is independent of signaling by the G protein-coupled receptor Smoothened.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: April 24, 2018
    Assignee: 4 SC AG
    Inventors: Fritz Aberger, Wolfgang Gruber, Johann Leban, Hella Kohlhof, Daniel Vitt, Roland Baumgartner
  • Enhancer of survival of transplanted organ
    Patent number: 9937138
    Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: April 10, 2018
    Assignees: National Center for Child Health and Development, SBI Pharmaceuticals Co., Ltd.
    Inventors: Ko Rii, Kiwamu Takahashi, Naomi Haga, Fuminori Abe, Tohru Tanaka, Motowo Nakajima, Hidenori Ito
  • Carbonyl erastin analogs and their use
    Patent number: 9938245
    Abstract: The present invention provides, inter alia, compounds having the structure of formula (I): Compositions containing such compounds are also provided. Methods for using such compounds or compositions for treating or ameliorating the effects of a cancer having a cell that harbors an oncogenic RAS mutation, for modulating a lipoxygenase in a ferroptosis cell death pathway, and for depleting reduced glutathione (GSH) in a cell harboring an oncogenic RAS mutation are further provided.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: April 10, 2018
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Brent R. Stockwell, Wan Seok Yang, Marie-Helene Larraufie
  • Methods of treating and preventing vascular instability diseases
    Patent number: 9937162
    Abstract: Methods are provided of treating and preventing stroke diseases, such as cerebral cavernous malformation, by the administration of tempol and/or cholecalciferol.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: April 10, 2018
    Assignee: THE UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Christopher C. Gibson, Dean Y. Li
  • Combinations of histone deacetylase inhibitors and bendamustine
    Patent number: 9937174
    Abstract: The invention relates to pharmaceutical combinations comprising an HDAC inhibitor and bendamustine; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions for treating lymphoma in a subject in need thereof.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: April 10, 2018
    Assignee: UNIVERSITY OF MODENA AND REGGIO EMILIA
    Inventors: Samantha Pozzi, Maria Cosenza
  • Transient protection of normal cells during chemotherapy
    Patent number: 9931345
    Abstract: This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: April 3, 2018
    Assignee: Presidents and Fellows of Harvard College
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
  • Ceftolozane-tazobactam pharmaceutical compositions
    Patent number: 9925196
    Abstract: Pharmaceutical compositions are provided in unit dosage forms comprising ceftolozane and tazobactam in separate unit dosage form containers, ceftolozane prepared in the absence of tazobactam, tazobactam prepared in the absence of ceftolozane, and/or compositions where ceftolozane and tazobactam are first combined within a unit dosage form container.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: March 27, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Joseph Terracciano, Nicole Miller Damour, Chun Jiang, Giovanni Fogliato, Giuseppe Alessandro Donadelli, Dario Resemini
  • Procedure for the preparation of 4-phenyl butyrate and uses thereof
    Patent number: 9914692
    Abstract: Provided is a process for preparing 4-phenyl-1-butyric acid, comprising: reacting 4-phenyl-1-butanol with sodium chlorite, a nitroxyl radical catalyst and sodium hypochlorite in an organic solvent and a phosphate buffer; and quenching the reaction with sodium sulfite to produce 4-phenyl-1-butyric. Also provided is 4-phenyl-1-butyric acid prepared by such a process.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: March 13, 2018
    Assignee: Horizon Therapeutics, LLC
    Inventors: Huai-Chueh Chang, Steven S. Pfeiffer, Vasilios H. Iskos, Maki Uragami, Steven Weissman, Andrew Thompson
  • Lysine demethylase inhibitors for myeloproliferative disorders
    Patent number: 9908859
    Abstract: The invention relates to methods and compositions for the treatment or prevention of diseases and disorders associated with myeloproliferative disorders. In particular, the invention relates to an LSD 1 inhibitor for use in treating or preventing Philadelphia chromosome negative myeloproliferative disorders.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: March 6, 2018
    Assignee: Oryzon Genomics, S.A.
    Inventors: Jonathan Alleman Baker, Julio Castro Palomino, Matthew Colin Thor Fyfe, Tamara Maes, Marc Martinell Pedemonte
  • Dalcetrapib for therapeutic use
    Patent number: 9909178
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: March 6, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • Methods of preparation and forming supported active metal catalysts and precursors
    Patent number: 9908110
    Abstract: The invention relates to a method of preparing a supported catalyst, which method comprises the steps of; (i) providing a porous catalyst support comprising a framework having an internal pore structure comprising one or more pores which internal pore structure comprises a precipitant; (ii) contacting the catalyst support with a solution or colloidal suspension comprising a catalytically active metal such that, on contact with the precipitant, particles comprising the catalytically active metal are precipitated within the internal pore structure of the framework of the catalyst support. The invention also relates to supported catalysts made according to the above method, and to use of the catalysts in catalyzing chemical reactions, for example in the Fischer Tropsch synthesis of hydrocarbons.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: March 6, 2018
    Assignee: IGTL TECHNOLOGY LTD.
    Inventor: Richard Hyman
  • Enhancer of survival of transplanted organ
    Patent number: 9901558
    Abstract: The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: February 27, 2018
    Assignees: National Center for Child Health and Development, SBI Pharmaceuticals Co., Ltd.
    Inventors: Ko Rii, Kiwamu Takahashi, Naomi Haga, Fuminori Abe, Tohru Tanaka, Motowo Nakajima, Hidenori Ito
  • Prostamides for the treatment of glaucoma and related diseases
    Patent number: 9890118
    Abstract: Disclosed herein are compositions comprising an amide related to a prostaglandin and a biogenic amine. Other aspects relate to certain chemical compounds, pharmaceutical compositions, and methods of treating glaucoma.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: February 13, 2018
    Assignee: ALLERGAN, INC.
    Inventors: David F. Woodward, Robert M. Burk
  • Pest control mixture
    Patent number: 9872497
    Abstract: A pesticidal mixture including (a) spinetoram; and (b) a compound of group A selected from novaluron, pyriproxyfen, tau-fluvalinate, and a combination thereof.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: January 23, 2018
    Assignee: MAKHTESHIM CHEMICAL WORKS LTD.
    Inventors: Assaf Dotan, Tamar Danon
  • Long-acting semi-solid lipid formulations
    Patent number: 9849180
    Abstract: What is described is a semi-solid controlled release composition comprising a semi-solid lipid pharmaceutical active agent in a solution or a homogenous suspension, methods of using the composition for treating a disease, and methods of manufacturing the composition.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: December 26, 2017
    Inventors: Hui Rong Shen, Na Gan
  • Composition comprising a complex of (+)-catechin and amino acid for the treatment and prevention of cancer
    Patent number: 9844595
    Abstract: The invention relates to a gastroenteric therapeutic composition for oral administration, comprising a compound of monomeric (+)-catechin and at least one basic amino acid, said composition being characterized in that it is used in the form of a complex of (+)-catechin and at least one basic amino acid or at least one derivative or precursor of a basic amino acid for the curative and/or preventive treatment of cancer, said complex having a molar equivalence ratio of the monomeric (+)-catechin to the at least one basic amino acid or the at least one basic amino acid derivative of between 1:1 and 1:2.5.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: December 19, 2017
    Assignee: Valore
    Inventors: Paul Niebes, Bronislav Henric May, Saïd Rachidi, Julien Estager, Bruno Schoentjes
  • Treatment of proteinopathies
    Patent number: 9845327
    Abstract: The present disclosure provides technologies relating to lysosomal activation. The disclosure provides several strategies for increasing level and/or activity of lysosomal enzyme, and furthermore demonstrates the surprising applicability of such strategies in the treatment and/or prophylaxis of certain proteinopathies. Among other things, the present invention provides methods and compositions for the treatment and/or prophylaxis of proteinopathies other than lysosomal storage diseases through lysosomal activation. In particular, the present disclosure provides methods and compositions for the treatment and/or prophylaxis of neurodegenerative proteinopathies, and in particular those associated with accumulation of ?-synuclein. The present disclosure specifically provides methods and compositions for the treatment and/or prophylaxis of Parkinson's disease.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: December 19, 2017
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Dmitri Krainc, Joseph R. Mazzulli